FDA Approves Vosevi (sofosbuvir, velpatasvir and voxilaprevir) for Hepatitis C

July 18, 2017 -- The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news